Carlos E Fardella

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5029156/publications.pdf

Version: 2024-02-01

77 papers 5,583 citations

147801 31 h-index 76900 74 g-index

83 all docs 83 docs citations

83 times ranked 4658 citing authors

#	Article	IF	CITATIONS
1	The impact of the micronutrient iodine in health and diseases. Critical Reviews in Food Science and Nutrition, 2022, 62, 1466-1479.	10.3	26
2	Plasminogen Activator Inhibitor-1 and Adiponectin Are Associated With Metabolic Syndrome Components. American Journal of Hypertension, 2022, 35, 311-318.	2.0	9
3	Aldosterone and renin concentrations were abnormally elevated in a cohort of normotensive pregnant women. Endocrine, 2022, 75, 899-906.	2.3	5
4	Primary Aldosteronism, Aldosterone, and Extracellular Vesicles. Endocrinology, 2022, 163, .	2.8	3
5	Clinical, biochemical, and miRNA profile of subjects with positive screening of primary aldosteronism and nonclassic apparent mineralocorticoid excess. Endocrine, 2022, 77, 380-391.	2.3	3
6	Proteomic Profile of Urinary Extracellular Vesicles Identifies AGP1 as a Potential Biomarker of Primary Aldosteronism. Endocrinology, 2021, 162, .	2.8	12
7	Extending the endocrine hypertension spectrum: novel nonclassic apparent mineralocorticoid excess. Endocrine, 2021, 74, 437-439.	2.3	3
8	Novel metabolomic profile of subjects with non-classic apparent mineralocorticoid excess. Scientific Reports, 2021, 11, 17156.	3.3	7
9	Serum Alpha-1-Acid Glycoprotein-1 and Urinary Extracellular Vesicle miR-21-5p as Potential Biomarkers of Primary Aldosteronism. Frontiers in Immunology, 2021, 12, 768734.	4.8	4
10	Classic and Nonclassic Apparent Mineralocorticoid Excess Syndrome. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e924-e936.	3.6	26
11	Urinary sodium-to-potassium ratio and plasma renin and aldosterone concentrations in normotensive children: implications for the interpretation of results. Journal of Hypertension, 2020, 38, 671-678.	0.5	5
12	Eplerenone Implantation Improved Adipose Dysfunction Averting RAAS Activation and Cell Division. Frontiers in Endocrinology, 2020, 11, 223.	3.5	16
13	The Aldosterone/Renin Ratio Predicts Cardiometabolic Disorders in Subjects Without Classic Primary Aldosteronism. American Journal of Hypertension, 2019, 32, 468-475.	2.0	13
14	Downregulation of exosomal miR-192-5p and miR-204-5p in subjects with nonclassic apparent mineralocorticoid excess. Journal of Translational Medicine, 2019, 17, 392.	4.4	17
15	Clinical, Biochemical, and Genetic Characteristics of "Nonclassic―Apparent Mineralocorticoid Excess Syndrome. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 595-603.	3.6	26
16	Serum Cortisol and Cortisone as Potential Biomarkers of Partial $11\hat{1}^2$ -Hydroxysteroid Dehydrogenase Type 2 Deficiency. American Journal of Hypertension, 2018, 31, 910-918.	2.0	19
17	Sodium Intake Is associated With Endothelial Damage Biomarkers and Metabolic Dysregulation. American Journal of Hypertension, 2018, 31, 1127-1132.	2.0	11
18	Depressive symptoms are associated with higher morning plasma cortisol in primary care subjects. Neuroendocrinology Letters, 2018, 39, 288-293.	0.2	1

#	Article	IF	Citations
19	Modulating the function of the immune system by thyroid hormones and thyrotropin. Immunology Letters, 2017, 184, 76-83.	2.5	86
20	Imprinting of maternal thyroid hormones in the offspring. International Reviews of Immunology, 2017, 36, 240-255.	3.3	14
21	Continuum of Renin-Independent Aldosteronism in Normotension. Hypertension, 2017, 69, 950-956.	2.7	122
22	Hypertensive Patients That Respond to Aldosterone Antagonists May Have a Nonclassical $11\hat{1}^2$ -HSD2 Deficiency. American Journal of Hypertension, 2017, 30, e6-e6.	2.0	8
23	Role of the Renin-Angiotensin-Aldosterone System beyond Blood Pressure Regulation: Molecular and Cellular Mechanisms Involved in End-Organ Damage during Arterial Hypertension. International Journal of Molecular Sciences, 2016, 17, 797.	4.1	197
24	Cortisol/cortisone ratio and matrix metalloproteinase-9 activity are associated with pediatric primary hypertension. Journal of Hypertension, 2016, 34, 1808-1814.	0.5	14
25	Usefulness and Pitfalls in Sodium Intake Estimation: Comparison of Dietary Assessment and Urinary Excretion in Chilean Children and Adults. American Journal of Hypertension, 2016, 29, 1212-1217.	2.0	20
26	Citosine-Adenine-Repeat Microsatellite of $11\hat{1}^2$ -hydroxysteroid dehydrogenase 2 Gene in Hypertensive Children. American Journal of Hypertension, 2016, 29, 25-32.	2.0	4
27	Aldosterone Production and Signaling Dysregulation in Obesity. Current Hypertension Reports, 2016, 18, 20.	3.5	66
28	Beneficial effects of mineralocorticoid receptor blockade in experimental nonâ€alcoholic steatohepatitis. Liver International, 2015, 35, 2129-2138.	3.9	48
29	The Expression of RAC1 and Mineralocorticoid Pathway-Dependent Genes are Associated With Different Responses to Salt Intake. American Journal of Hypertension, 2015, 28, 722-728.	2.0	13
30	Epigenetics and arterial hypertension: the challenge of emerging evidence. Translational Research, 2015, 165, 154-165.	5.0	83
31	Identification of novel $11\hat{l}^2$ -HSD1 inhibitors by combined ligand- and structure-based virtual screening. Molecular and Cellular Endocrinology, 2014, 384, 71-82.	3.2	12
32	LC–MS/MS Method for the Simultaneous Determination of Free Urinary Steroids. Chromatographia, 2014, 77, 637-642.	1.3	29
33	High sodium intake is associated with increased glucocorticoid production, insulin resistance and metabolic syndrome. Clinical Endocrinology, 2014, 80, 677-684.	2.4	143
34	Age-Related Changes in 11Â-Hydroxysteroid Dehydrogenase Type 2 Activity in Normotensive Subjects. American Journal of Hypertension, 2013, 26, 481-487.	2.0	48
35	Different effects of progesterone and estradiol on chimeric and wild type aldosterone synthase in vitro. Reproductive Biology and Endocrinology, 2013, 11, 76.	3.3	14
36	Positive association between aldosteroneâ€renin ratio and carotid intimaâ€media thickness in hypertensive children. Clinical Endocrinology, 2013, 78, 352-357.	2.4	14

#	Article	IF	CITATIONS
37	Overexpression of $11\hat{1}^2\hat{a}\in$ hydroxysteroid dehydrogenase type 1 in visceral adipose tissue and portal hypercortisolism in nonâ \in alcoholic fatty liver disease. Liver International, 2012, 32, 392-399.	3.9	42
38	11Â-Hydroxysteroid Dehydrogenase Type 2 Polymorphisms and Activity in a Chilean Essential Hypertensive and Normotensive Cohort. American Journal of Hypertension, 2012, 25, 597-603.	2.0	12
39	A New Presentation of the Chimeric CYP11B1/CYP11B2 Gene With Low Prevalence of Primary Aldosteronism and Atypical Gene Segregation Pattern. Hypertension, 2012, 59, 85-91.	2.7	18
40	Birth weight is inversely associated with blood pressure and serum aldosterone and cortisol levels in children. Clinical Endocrinology, 2012, 76, 713-718.	2.4	40
41	A de novo unequal cross-over mutation between CYP11B1 and CYP11B2 genes causes familial hyperaldosteronism type I. Journal of Endocrinological Investigation, 2011, 34, 140-144.	3.3	12
42	Increased urinary glucocorticoid metabolites are associated with metabolic syndrome, hypoadiponectinemia, insulin resistance and \hat{l}^2 cell dysfunction. Steroids, 2011, 76, 1575-1581.	1.8	33
43	Aldosterone as a modulator of immunity. Journal of Hypertension, 2011, 29, 1684-1692.	0.5	57
44	Overexpression of hepatic $5l\pm$ -reductase and $11l^2$ -hydroxysteroid dehydrogenase type 1 in visceral adipose tissue is associated with hyperinsulinemia in morbidly obese patients. Metabolism: Clinical and Experimental, 2011, 60, 1775-1780.	3.4	34
45	Frequency of Familial Hyperaldosteronism Type 1 in a Hypertensive Pediatric Population. Hypertension, 2011, 57, 1117-1121.	2.7	55
46	Increased levels of oxidative stress, subclinical inflammation, and myocardial fibrosis markers in primary aldosteronism patients. Journal of Hypertension, 2010, 28, 2120-2126.	0.5	76
47	$11\hat{l}^2$ -hydroxysteroid dehydrogenase type-2 and type-1 ($11\hat{l}^2$ -HSD2 and $11\hat{l}^2$ -HSD1) and $5\hat{l}^2$ -reductase activities in t pathogenia of essential hypertension. Endocrine, 2010, 37, 106-114.	:he 2.3	39
48	Overexpression of $11\hat{1}^2$ -Hydroxysteroid Dehydrogenase Type 1 in Hepatic and Visceral Adipose Tissue is Associated with Metabolic Disorders in Morbidly Obese Patients. Obesity Surgery, 2010, 20, 77-83.	2.1	56
49	Primary Aldosteronism and its Impact on the Generation of Arterial Hypertension, Endothelial Injury and Oxidative Stress. Journal of Pediatric Endocrinology and Metabolism, 2010, 23, 323-30.	0.9	11
50	Aldosterone Promotes Autoimmune Damage by Enhancing Th17-Mediated Immunity. Journal of Immunology, 2010, 184, 191-202.	0.8	147
51	Aldosterone, Plasma Renin Activity, and Aldosterone/Renin Ratio in a Normotensive Healthy Pediatric Population. Hypertension, 2010, 56, 391-396.	2.7	41
52	Genetics of Hypertensive Syndrome. Hormone Research in Paediatrics, 2009, 71, 253-259.	1.8	21
53	$11\hat{l}^2$ -Hydroxysteroid Dehydrogenase Type 1 is Overexpressed in Subcutaneous Adipose Tissue of Morbidly Obese Patients. Obesity Surgery, 2009, 19, 764-770.	2.1	32
54	Primary aldosteronism can alter peripheral levels of transforming growth factor \hat{l}^2 and tumor necrosis factor \hat{l}_{\pm} . Journal of Endocrinological Investigation, 2009, 32, 759-765.	3.3	34

#	Article	IF	CITATIONS
55	Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3266-3281.	3.6	1,440
56	A possible association between primary aldosteronism and a lower \hat{l}^2 -cell function. Journal of Hypertension, 2008, 26, 609-610.	0.5	1
57	Hiperaldosteronismo primario. Revista Medica De Chile, 2008, 136, .	0.2	4
58	A possible association between primary aldosteronism and a lower \hat{l}^2 -cell function. Journal of Hypertension, 2007, 25, 2125-2130.	0.5	88
59	A Polymorphic GT Short Tandem Repeat Affecting \hat{l}^2 -ENaC mRNA Expression Is Associated With Low Renin Essential Hypertension. American Journal of Hypertension, 2007, 20, 800-806.	2.0	10
60	Refractory depression in a patient with peripheral resistance to thyroid hormone (RTH) and the effect of triiodothyronine treatment. Endocrine, 2007, 31, 272-278.	2.2	7
61	Comparison of Confirmatory Tests for the Diagnosis of Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2618-2623.	3.6	174
62	New splicing mutation of MEN1 gene affecting the translocation of menin to the nucleous. Journal of Endocrinological Investigation, 2006, 29, 888-893.	3.3	6
63	Association of adrenal medullar and cortical nodular hyperplasia. Endocrine, 2006, 30, 389-396.	2.2	4
64	Primary Hyperaldosteronism in the Hypertensive Disease. Current Hypertension Reviews, 2006, 2, 33-40.	0.9	3
65	Biochemical and genetic characterization of 11 ??-hydroxysteroid dehydrogenase type 2 in low-renin essential hypertensives. Journal of Hypertension, 2005, 23, 71-77.	0.5	34
66	Increased Diagnosis of Primary Aldosteronism, Including Surgically Correctable Forms, in Centers from Five Continents. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1045-1050.	3.6	862
67	Primary Aldosteronism and Hypertensive Disease. Hypertension, 2003, 42, 161-165.	2.7	433
68	Two Homozygous Mutations in the $11\hat{l}^2$ -Hydroxysteroid Dehydrogenase Type 2 Gene in a Case of Apparent Mineralocorticoid Excess. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 2501-2507.	3.6	45
69	Neurobehavioral and psychological changes induced by hyperthyroidism: diagnostic and therapeutic implications. Expert Review of Neurotherapeutics, 2002, 2, 709-716.	2.8	2
70	Primary aldosteronism. Clinical Laboratory, 2002, 48, 181-90.	0.5	11
71	Cautions over idiopathic aldosteronism. Lancet, The, 2001, 358, 333-334.	13.7	3
72	Authors' Response: Prevalence of Primary Aldosteronism in Unselected Hypertensive Populations—Screening and Definitive Diagnosis. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 4003-4004.	3.6	10

#	Article	IF	CITATIONS
73	Serum 18-Hydroxycortisol in Primary Aldosteronism, Hypertension, and Normotensives. Hypertension, 2001, 38, 688-691.	2.7	47
74	Genetic Study of Patients with Dexamethasone-Suppressible Aldosteronism without the Chimeric CYP11B1/CYP11B2 Gene. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 4805-4807.	3 . 6	31
75	Primary Hyperaldosteronism in Essential Hypertensives: Prevalence, Biochemical Profile, and Molecular Biology $<$ sup $<$ 1 $<$ 1 $<$ 1 Sup $<$ 1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1863-1867.	3.6	381
76	High prevalence of thyroid abnormalities in a Chilean psychiatric outpatient population. Journal of Endocrinological Investigation, 2000, 23, 102-106.	3.3	21
77	Intracellular calcium and blood pressure: Comparison between primary hyperparathyroidism and essential hypertension. Journal of Endocrinological Investigation, 1995, 18, 827-832.	3.3	43